David Dai
Stock Analyst at UBS
(0.19)
# 3,850
Out of 4,667 analysts
18
Total ratings
16.67%
Success rate
-20.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $32.42 | -25.97% | 1 | Oct 24, 2024 | |
| NUVL Nuvalent | Initiates: Neutral | $100 | $91.17 | +9.69% | 1 | Oct 24, 2024 | |
| BPMC Blueprint Medicines | Initiates: Neutral | $88 | $94.81 | -7.18% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $6.17 | +224.15% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $22.64 | +54.59% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $42.93 | +67.71% | 1 | Oct 24, 2024 | |
| KURA Kura Oncology | Initiates: Buy | $27 | $15.91 | +69.70% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $48.96 | +40.93% | 1 | Oct 24, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $25.54 | +95.77% | 1 | Oct 24, 2024 | |
| IOVA Iovance Biotherapeutics | Initiates: Buy | $17 | $8.14 | +108.85% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $12.58 | +138.47% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $32.24 | +86.10% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $15.95 | +131.97% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.97 | +2,795.25% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $14.04 | +184.90% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $3.28 | +1,119.51% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.50 | +1,900.00% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $35.18 | +47.81% | 1 | Mar 17, 2020 |
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $32.42
Upside: -25.97%
Nuvalent
Oct 24, 2024
Initiates: Neutral
Price Target: $100
Current: $91.17
Upside: +9.69%
Blueprint Medicines
Oct 24, 2024
Initiates: Neutral
Price Target: $88
Current: $94.81
Upside: -7.18%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $6.17
Upside: +224.15%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $22.64
Upside: +54.59%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $42.93
Upside: +67.71%
Kura Oncology
Oct 24, 2024
Initiates: Buy
Price Target: $27
Current: $15.91
Upside: +69.70%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $48.96
Upside: +40.93%
IDEAYA Biosciences
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $25.54
Upside: +95.77%
Iovance Biotherapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $17
Current: $8.14
Upside: +108.85%
Oct 24, 2024
Initiates: Buy
Price Target: $30
Current: $12.58
Upside: +138.47%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $32.24
Upside: +86.10%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $15.95
Upside: +131.97%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.97
Upside: +2,795.25%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $14.04
Upside: +184.90%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $3.28
Upside: +1,119.51%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.50
Upside: +1,900.00%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $35.18
Upside: +47.81%